Try Alerts Free   |   Login
Health Care › Surgical & Medical Instruments & Apparatus

NPCE Price Correlated With Financials For NeuroPace

Free historical financial statements for NeuroPace Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 7 quarters since 2021. Compare with NPCE stock chart to see long term trends.

NPCE Stock Compared to Quarterly

NPCE Income Statement

Revenue, Net:11157000
Revenue Per Share:0.448
Cost of Goods & Services Sold:3192000
Gross Profit:7965000
Selling, General & Admin Expense:12553000
Research & Development Expense:5611000
Total Operating Expenses:18164000
Operating Income:-10199000
Income Taxes:0
Net Income:-11785000
Earnings Per Share, Basic:-0.48
Shares Outstanding, Basic Avg:24903146

NPCE Cash Flow

Operating Activities Net Income:
Change in Accounts Receiveable:-601000
Net Cash from Operations:-6975000
Net Cash from Operations Per Share:-0.2801
Cash Dividends Paid:0
Net Cash from Financing Activities:-8000
Property, Plant & Equipment Purchases:31000
Net Cash from Investing Activities:6969000
Net Change in Cash & Equivalents:-14000

NPCE Balance Sheet

Cash and Cash Equivalents:85400000
Short-Term Investments:null
Accounts Receivable, Net:7876000
Inventories:8581000
Total Current Assets:104370000
Property, Plant & Equipment, Net:894000
Total Assets:120474000
Accounts Payable:1175000
Current Portion of Long-Term Debt:null
Total Short-Term Liabilities:9417000
Long Term Debt, Non-Current Portion:51954000
Total Liabilities:77065000

Insider Trading

 
Change
Value
Transaction
SEC Form 4
Accelmed Partners II L.P.   10% Owner
390,291 sh at $2
$585,046
Buy

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Kck Ltd.
5,621,111 sh
 
$21,079
Orbimed Advisors LLC
4,012,281 sh
 
$15,046
Soleus Capital Management, L.P.
2,334,003 sh
 
$8,753
Morgan Stanley
2,123,603 sh
138,414 sh
7%
$7,963
-$1,863
FMR LLC
1,449,926 sh
30,975 sh
2%
$5,437
-$1,587
Millennium Management LLC
585,367 sh
78,462 sh
15%
$2,195
-$314
Nantahala Capital Management, LLC
443,502 sh
-34,936 sh
-7%
$1,663
-$705
American Century Companies Inc
395,746 sh
-177,412 sh
-31%
$1,484
-$1,353
Bellevue Group Ag
388,368 sh
-119,562 sh
-24%
$1,456
-$1,058
Vanguard Group Inc
273,796 sh
 
$1,026
Point72 Asset Management, L.P.
145,703 sh
-3,496 sh
-2%
$546
-$193
Opaleye Management Inc.
116,324 sh
26,224 sh
29%
$436
-$10
Geode Capital Management, LLC
65,570 sh
 
$245
Revelation Capital Management, LLC
42,972 sh
-205,155 sh
-83%
$161
-$1,067
Bridgeway Capital Management Inc
31,648 sh
5,500 sh
21%
$119
-$10
Ergoteles LLC
31,027 sh
-3,773 sh
-11%
$116
-$56
Blackrock Inc.
25,446 sh
3,360 sh
15%
$95
-$14
State Street Corp
22,451 sh
 
$84
Northern Trust Corp
16,171 sh
-44,013 sh
-73%
$61
-$433
Renaissance Technologies LLC
13,200 sh
13,200 sh
NEW
$50
$50
COMPANY PROFILE
The Company NeuroPace, Inc., or the Company, was incorporated in the state of Delaware on November 19, 1997. The Company is a commercial-stage medical device company that has developed the RNS System, the only commercially available brain-responsive neuromodulation system designed for treating medically refractory focal epilepsy by delivering personalized, real-time treatment at the seizure source. The Company began commercializing its products in the United States in 2014.

Initial Public Offering

On April 21, 2021, the Company’s registration statement on Form S-1 (File No. 333-254663) relating to its initial public offering, or IPO, of common stock became effective. The IPO closed on April 26, 2021, at which time the Company issued 6,900,000 shares of its common stock at a price of $17.00 per share, which included the issuance of shares in connection with the exercise by the underwriters of their option to purchase up to 900,000 additional shares. The Company received an aggregate of $117.3 million in gross proceeds, before underwriting discounts and commissions and offering costs, and approximately $105.5 million in net proceeds after deducting $8.2 million in underwriting discounts and commissions and $3.6 million in offering costs.

Upon the closing of the IPO, all outstanding shares of the Company’s redeemable convertible preferred stock converted into 16,614,178 shares of common stock, warrants to purchase 346,823 shares of Series B’ convertible preferred stock net exercised to 213,941 shares of Series B’ convertible preferred stock and subsequently converted into common stock on a one-to-one basis, and warrants to purchase 219 shares of common stock net exercised to 185 shares of common stock. In connection with the completion of its IPO, on April 26, 2021, the Company’s certificate of incorporation was amended and restated to provide for 200,000,000 authorized shares of common stock with a par value of $0.001 per share and 10,000,000 authorized shares of preferred stock with a par value of $0.001 per share.

Liquidity and Capital Resources

The Company has incurred operating losses and negative cash flows from operations since its inception and has an accumulated deficit of $435.2 million as of March 31, 2022. For the three months ended March 31, 2022 and 2021, the Company used $11.4 million and $5.9 million of cash, respectively, in its operating activities. As of March 31, 2022, the Company had cash, cash equivalents and short-term investments of $103.2 million. Historically, the Company has funded its operations principally through the sales of its products, issuance of redeemable convertible preferred stock and debt financing. On April 26, 2021, the Company completed its IPO and received approximately $105.5 million in net proceeds after deducting underwriting discounts, commissions and offering costs.

The Company’s condensed financial statements have been prepared on the basis of the Company continuing as a going concern for the next 12 months. Management believes that the Company’s cash, cash equivalents and short-term investments will allow the Company to continue its planned operations for at least the next 12 months from the date of the issuance of these unaudited interim condensed financial statements.

In connection with the Term Loan described in Note 6, the Company will need to be in compliance with a minimum annual net revenue covenant determined in accordance with generally accepted accounting principles of $43.0 million in the year ended December 31, 2022, and maintain a minimum cash and cash equivalents balance of $5.0 million . If the Company cannot generate sufficient revenue in the future, the Company may not be in compliance with the annual net revenue covenant and the lender may call the debt resulting in the Company immediately needing additional funds, and resulting in a going concern. As of March 31, 2022 , the Company was in compliance with all covenants of the Term Loan.

The COVID-19 pand

Data imported from NeuroPace Inc. SEC filings. Check original filings before making any investment decision.